Medical Devices
The Blood Industry
| Publication Date | March 2008 |
| Publisher | BCC Research |
| Product Type | Report |
| Pages | 225 |
| ISBN Number | not applicable |
| Product Code | BCC00017 |
Price
£3,205.00
approximately: $4,853 | €3,577
approximately: $4,853 | €3,577
Order above formats by FAX
Summary
Introduction
The goal of this study on the blood industry is to describe and analyze the current markets for blood products, blood tests, and blood processing equipment as well as present important new developments affecting every aspect of this industry. In addition, the report provides an analysis of market value forecasted through 2012 in constant dollars and participating company profiles. The study covers the major aspects of blood and plasma collection/transfusion, including autologous donations, apheresis, fractionation, blood salvage, and stem cells. The major plasma products such as coagulation factors, human serum albumin, and immunoglobulins are analyzed as well. The scope and character of the blood testing segment is constantly changing so the impact of new products, technologies, and equipment are analyzed.
The study also covers federal regulation of the blood supply, blood system management, an analysis of the companies serving these markets, the international developments in blood banking, and related areas as well as research and patents that will affect the future of the blood industry.
Scope Of Study
This report contains:
- Descriptions of various types of blood and plasma collection and transfusion technologies including autologous donations, apheresis, fractionation, blood salvage and stem cells, and major plasma products such as coagulation factors, human serum albumin
- The current U.S. blood industry market status, with trends and forecasts for growth over the next 5 years
- Technological issues including the latest trends and a thorough patent analysis
- Analysis of federal regulations concerning blood supply and management
- Discussion of the international markets for various blood and blood-related products.
Methodology And Information Sources
Data for this study were collected using both primary and secondary data research techniques. A literature search of BCC's extensive library as well as scientific, medical, and business libraries was conducted. On-line databases and government sources were consulted as well. Extensive interviews with industry personnel, scientists, professional and trade organizations, government agency personnel, observers, scientists, and industry professionals were conducted.
Data collected were analyzed by BCC personnel to determine specific findings and forecasts. Once these forecasts were obtained, they were validated with industry experts; consequently, all estimates provided in this report represent a consensus of BCC personnel, industry participants, and industry observers. Since some segments of this report are not routinely measured, BCC derived estimates from a variety of analogous sources. Whenever market estimates are derived, they are fully noted. It should be pointed out that while many factors were considered in constructing different models, the projections are ultimately speculative. As a composite of the opinions and assessments of interviewees, the author, other analysts, and secondary sources, these projections represent something of a consensus. However, all recognize that the relative importance of selected factors could change at any time with new technologies and new products and, thus, change the direction of the market projections. All forecasts use constant 2007 dollars.
Analyst Credentials
Mary Anne Crandall is an expert industry analyst who has specialized in the pharmaceutical industry for the past 15 years. She has completed several in-depth studies on various medical topics, which has required both medical expertise and excellent knowledge of the pharmaceutical industry. Crandall has a master's degree in psychology, a PhD in natural health, and is a registered nurse (RN)/instructor at Southern Oregon University (Ashland, OR).
Contents
- Major Findings
- Summary Table: U.S. Blood Market, Through 2012 ($ Millions)
- Summary Figure: U.S. Blood Market, 2007 And 2012 ($ Millions)
- The Blood Industry
- Market Structure And Size
- Table 1 U.S. Blood Products And Collection And Processing Products Market, Through 2012 ($ Millions)
- History Of The Blood Industry
- Table 2 Timeline Of The Blood Industry
- Table 2
- Blood And Its Components
- Plasma
- Table 3 Composition Of Blood
- Cellular Elements
- Red And White Blood Cells
- Platelets
- Immunoglobulin Products
- The Dangers Of Transfused Blood
- Transfusion Associated Risks
- Diseases Contracted From Blood Transfusions And Related Identification Testing
- Table 4 Major Diseases Contracted From Blood Transfusions
- Table 4
- Hiv/Aids
- Table 5 Cber-Licensed Hiv Donor Screening Tests
- Table 5
- Hepatitis A
- Hepatitis B
- Table 6 Cber-Licensed Screening Tests For Hepatitis B
- Hepatitis C
- Table 7 Cber-Licensed Screening Tests For Hepatitis C
- Hepatitis D
- Hepatitis E
- Human T Cell Lymphotropic Virus-(Htlv-I, -Ii)
- Table 8 Cber-Licensed Screening Tests For Htlv-I And Htlv-Ii
- Cytomegalovirus
- Table 9 Cber-Licensed Screening Tests For Cmv
- Table 9
- Table 10 Cber-Licensed Screening Tests For West Nile
- The Blood Industry
- Market Structure And Size
- Table 1 U.S. Blood Products And Collection And Processing Products Market, Through 2012 ($ Millions)
- History Of The Blood Industry
- Table 2 Timeline Of The Blood Industry
- Table 2
- Blood And Its Components
- Plasma
- Table 3 Composition Of Blood
- Cellular Elements
- Red And White Blood Cells
- Platelets
- Immunoglobulin Products
- The Dangers Of Transfused Blood
- Transfusion Associated Risks
- Diseases Contracted From Blood Transfusions And Related Identification Testing
- Table 4 Major Diseases Contracted From Blood Transfusions
- Table 4
- Hiv/Aids
- Table 5 Cber-Licensed Hiv Donor Screening Tests
- Table 5
- Hepatitis A
- Hepatitis B
- Table 6 Cber-Licensed Screening Tests For Hepatitis B
- Hepatitis C
- Table 7 Cber-Licensed Screening Tests For Hepatitis C
- Hepatitis D
- Hepatitis E
- Human T Cell Lymphotropic Virus-(Htlv-I, -Ii)
- Table 8 Cber-Licensed Screening Tests For Htlv-I And Htlv-Ii
- Cytomegalovirus
- Table 9 Cber-Licensed Screening Tests For Cmv
- Table 9
- Table 10 Cber-Licensed Screening Tests For West Nile
- Classical Fractionation Methods
- Cohn Fractionation
- Advanced Fractionation Methods
- Amplification Methods
- Polymerase Chain Reaction (Pcr)
- Nucleic Amplification Technology (Nat)
- Immunoassay
- Enzyme Immunoassay (Eia)
- Basic Eia
- Figure 12 The Basic Enzyme Immunoassay (Eia) Process
- Alternate Eia Methods
- Second Antibody Precipitation Method
- Double Antibody Sandwich Method
- Reverse Sandwich Method
- Reverse Sandwich Inhibition Method
- Reverse Sandwich (Continued)
- Driving Forces Of The Industry
- Figure 1 Variables Influencing The Dynamics Of Demand For Blood For Transfusion
- Market Overview
- Figure 2 Blood Market Cost And Pricing Analysis
- Blood Collection Data
- Table 20 U.S. Blood Collection And Transfusion Data, Through 2012 (Million Units/Pts.)
- Figure 3 U.S. Blood Collection And Transfusion Data, 2005-2012 (Million Units/Pts.)
- Table 21 U.S. Plasma Collection Data, Through 2012 (Million Units/L)
- Figure 4 U.S. Plasma Collection Data, 2005-2012 (Million Units/L)
- Changing Patterns Of Transfusion Procedures
- Leukoreduction
- Impact Of Autologous Donations
- Types Of Autologous Transfusions
- Risks Of Pabd
- Pricing Of Blood
- Table 22 Cost Of Blood Components, Through 2012 ($)
- National Blood Exchange (Nbe)
- Rbcs And Leukoreduced Rbcs
- Platelets
- Random Donor Platelets
- Fresh Frozen Plasma (Ffp)
- Cryoprecipitate
- Washed Cells
- Deglycerolized Cells
- Other Blood Components
- Granulocytes
- Gamma-Irradiated Blood
- Average Cost Of Transfusion
- Table 23 Average Cost Of Transfusion To Patient By Product Type, 2007 ($)
- Plasma And Plasma-Derived Products
- Plasma Market Size
- Plasma Therapeutic Products
- Table 24 U.S. Market Size Plasma Therapeutic Derivatives By Type, Through 2012 ($ Millions)
- Figure 5 Share Of Plasma Therapeutic Derivatives By Type, 2007 And 2012 (%)
- Albumin And Plasma Protein Fraction (Ppf)
- Fda Notification Regarding Safety Of Albumin Administration In Critically Ill
- Recombinant Human Albumin
- Albumin Market Dynamics
- Table 25 Currently Marketed Albumin And Plasma Protein Fraction (Ppf) Products
- Albumin And Ppf Market Size
- Table 26 U.S. Market For Human Serum Albumin And Ppf, Through 2012 (Units, Price, And Value)
- Clotting Factors
- Table 27 Blood Clotting Factors
- Hemophilia
- Table 28 Worldwide And U.S.Hemophilia Statistics, 2007
- Market Demand And Market Size
- Table 29 U.S. Market For Plasma-Derived And Recombinant Clotting Factors, Through 2012 ($ Millions)
- Figure 6 U.S. Share For Plasma-Derived And Recombinant Clotting Factors, 2007 And 2012 (%)
- Factor Viii
- Table 30 Fda-Approved Factor Viii Products
- Table 30
- Factor Viii (Continued)
- Table 31 U.S. Market Share Factor Viii Companies, 2007
- Figure 7 Market Share Of Factor Viii Companies, 2007 (%)
- Factor Ix
- Table 32 Fda-Approved Factor Ix Products
- Factor Viia
- Other Factors
- Prothrombin Complex Concentrates
- Table 33 Fda-Approved Prothrombin Complex Concentrate Products
- Fibrin Sealants And Thrombin
- Table 34 U.S. Market For Fibrin/Thrombin, Through 2012 ($ Millions)
- Antithrombin Iii
- Table 35 U.S. Market For Antithrombin Iii-Thrombate, Through 2012 ($ Millions)
- Immunoglobulins
- Ivig
- Table 36 Selected Conditions Treated By Ivig
- Table 37 Fda-Approved Immunoglobulins
- Hyperimmunes
- Table 38 Fda-Approved Hyperimmune Immunoglobulins
- Table 38
- Other
- Imig
- Immunoglobulin Market Size
- Table 39 U.S. Market For Immunoglobulins By Type, Through 2012 ($ Millions)
- Figure 8 U.S. Market For Immunoglobulins By Type, 2007 And 2012 ($ Millions)
- Rsv
- Cmv Immunoglobulin
- Hepatitis B Immune Globulin
- Rhod Immunoglobulin
- Tetanus Immunoglobulin (Tig)
- Rabies Immunoglobulin
- Varicella Immunoglobulin
- Vaccinia Immune Globulin Intravenous (Vig)
- Alpha-1-Proteinase Inhibitor
- Alpha-1-Proteinase (Continued)
- Chapter- 6: Blood Testing And Typing Markets
- Market Size
- Table 40 Value U.S. Blood Typing And Blood Screening Market, Through 2012 ($ Millions)
- Figure 9 Value And Market Share Of U.S. Blood Typing And Blood Screening Market, 2007 And 2012 (%)
- Types Of Testing
- Polymerase Chain Reaction (Pcr) Amplification
- Table 41 Cber-Licensed Pcr Screening Tests
- Table 41
- Nucleic Acid Amplification Test (Nat)
- Table 42 Cber-Licensed Nat Donor Screening Tests
- Immunoassay
- Table 43 Immunoassay Cber-Licensed Screening Tests
- Table 43
- Market Size Blood Testing Products For Donor Screening
- Table 44 Average Cost Of Donor Blood Testing, 2007 And 2012 ($ Millions)
- Table 45 The U.S. Blood Donor Screening Testing Market By Type Of Tests, Through 2012 ($ Millions)
- Figure 10 U.S. Blood Donor Screening Testing Market By Type, 2007 And 2012 ($ Millions)
- Market Participants Donor Screening Products
- Table 46 List Of Suppliers Donor Screening Tests
- Blood Typing
- Market Size Blood Typing
- Table 47 The U.S. Blood Typing Market-Instruments And Supplies By Type, Through 2012 ($ Millions)
- Market Structure And Participants
- Manual Typing Methods
- Automated Blood Typing
- Immucor
- Ortho
- Olympus
- Blood Collection/Transfusion Products And Processing Equipment And Supplies
- Table 48 U.S. Market For Blood And Plasma Collection/Transfusion Products, Through 2012 ($ Millions)
- Collection Products
- Table 49 U.S. Market For Collection Products By Type, Through 2012 ($ Millions)
- Plasma And Blood Collection Equipment
- Table 50 U.S. Market For Blood And Plasma Collection Equipment By Type, Through 2012 ($ Millions)
- Figure 11 Share Of U.S. Market For Blood And Plasma Collection Products By Type, 2007 And 2012 (%)
- Blood Salvage
- Other Collection Equipment
- Table 51 U.S. Market For Other Plasma Collection Products, Through 2012 ($ Millions)
- Market Participants
- Haemonetics
- Pcs2
- Tcd Total Containment Unit
- Mcs+ 8150 System
- Cell Saver System
- Orthopat System
- Acp 215 System
- Baxter
- Autopheresis-C
- Alyx Component Collection System
- Cs-3000 Plus Blood Cell Separator
- Amicus Separator
- Gambro Bct
- Plasma Collection Sets
- Table 52 U.S. Market For Plasma Collection Sets, Through 2012 ($ Millions)
- Blood Bags
- Table 53 U.S. Market For Blood Bags, Through 2012 ($ Millions)
- Transfusion Products
- Table 54 U.S. Market For Transfusion Products By Type, Through 2012 ($ Millions)
- Transfusion Sets
- Table 55 U.S. Market For Transfusion Sets, Through 2012 ($ Millions)
- Blood Filter Market
- Table 56 U.S. Market For Filters, Through 2012 ($ Millions)
- Accessories
- Table 57 U.S. Market For Transfusion Accessories, Through 2012 ($ Millions)
- Chapter- 7: Technology
- Classical Fractionation Methods
- Cohn Fractionation
- Advanced Fractionation Methods
- Amplification Methods
- Polymerase Chain Reaction (Pcr)
- Nucleic Amplification Technology (Nat)
- Immunoassay
- Enzyme Immunoassay (Eia)
- Basic Eia
- Figure 12 The Basic Enzyme Immunoassay (Eia) Process
- Alternate Eia Methods
- Second Antibody Precipitation Method
- Double Antibody Sandwich Method
- Reverse Sandwich Method
- Reverse Sandwich Inhibition Method
- Reverse Sandwich (Continued)
- Chapter- 8: Blood Industry: International Analysis
- Regulation Of The U.S. Blood Business
- Table 16 Federal Organizations Responsible For U.S. Blood Safety
- Table 16
- Statutory Authority Of The Fda
- Center For Biologics Evaluation And Research
- Office Of Regulatory Affairs (Ora)
- Office Of Biologics, The Division Of Blood And Blood Products
- Table 17fda Authority In Regulating Blood Banking And Blood Products
- The Major Regulations And Policy Matters Concerning The U.S.Blood Supply
- The Clinical Laboratory Improvement Act Of 1988 (Clia)
- The Fda's Five Layers
- The Fda Blood Action Plan
- Table 18 Main Blood Regulation Issues Identified By The Fda
- Table 18
- Team Biologics
- How Regulations Get Implemented
- Inspecting Blood Banks And Plasma Collection Facilities
- Table 1914 Major Areas Of Concern For Inspecting Blood Facilities
- Other Organizations Involved In Blood Regulation
- National Heart, Lung, And Blood Institute (Nhlbi)
- Blood Diseases And Resources Program
- Occupational Safety And Health Administration (Osha)
- Health Care Financing Administration (Hcfa)
- The Department Of Defense
- State Regulatory Agencies
- Voluntary Regulation By Professional And Trade Associations
- American Association Of Blood Banks
- American Blood Resources Association
- America's Blood Centers (Abc)
- Ppta: Plasma Products Therapeutics Association
- The European Union (Eu) Blood Directive
- International Society For Blood Transfusion (Isbt)
- The Future Of Blood Regulation
- Chapter- 9: Blood Research And Development
- Dedicated Blood Research Facilities
- Jerome H. Holland Laboratory (Arc)
- National Blood Foundation (Nbf)
- Center For Blood Research (Cbr)
- Center For Blood Research (Cbr)(Continued)
- Center For Blood Research (Cbr)(Continued)
- Center For Blood Research (Cbr)(Continued)
- Table 62 Selected Advances In Adult Stem Cell Therapies
- Table 62
- Blood Substitutes
- Blood Substitutes
- Fibrin Sealant
- The Veterinary Blood Market
- Table 63 Regional Veterinary Blood Banks
- The Veterinary Blood Market
- Chapter- 10: Company Profiles
- Abbott Laboratories
- America's Blood Centers
- American Association Of Blood Banks (Aabb)
- American Red Cross (Arc)
- Baxter International, Inc
- Bio-Rad Laboratories
- Csl Behring
- Grifols Biologicals, Inc
- Grifols Biologicals, Inc.
- Haemonetics, Inc
- Immucor
- Massachusetts Public Health Biologic Labs
- Medimmune Corporation
- Ortho-Clinical Diagnostics
- Olympus Diagnostic Systems
- Talecris Biotherapeutics
- Chapter- 11: Patent Analysis
